Literature DB >> 21920899

SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer.

Selvakumar Elangovan1, Sabarish Ramachandran, Narayanan Venkatesan, Sudha Ananth, Jaya P Gnana-Prakasam, Pamela M Martin, Darren D Browning, Patricia V Schoenlein, Puttur D Prasad, Vadivel Ganapathy, Muthusamy Thangaraju.   

Abstract

The NAD-dependent histone deacetylase silent information regulator 1 (SIRT1) is overexpressed and catalytically activated in a number of human cancers, but recent studies have actually suggested that it may function as a tumor suppressor and metastasis inhibitor in vivo. In breast cancer, SIRT1 stabilization has been suggested to contribute to the oncogenic potential of the estrogen receptor α (ERα), but SIRT1 activity has also been associated with ERα deacetylation and inactivation. In this study, we show that SIRT1 is critical for estrogen to promote breast cancer. ERα physically interacted and functionally cooperated with SIRT1 in breast cancer cells. ERα also bound to the promoter for SIRT1 and increased its transcription. SIRT1 expression induced by ERα was sufficient to activate antioxidant and prosurvival genes in breast cancer cells, such as catalase and glutathione peroxidase, and to inactivate tumor suppressor genes such as cyclin G2 (CCNG2) and p53. Moreover, SIRT1 inactivation eliminated estrogen/ERα-induced cell growth and tumor development, triggering apoptosis. Taken together, these results indicated that SIRT1 is required for estrogen-induced breast cancer growth. Our findings imply that the combination of SIRT1 inhibitors and antiestrogen compounds may offer more effective treatment strategies for breast cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920899      PMCID: PMC3206200          DOI: 10.1158/0008-5472.CAN-11-1446

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Nutrient availability regulates SIRT1 through a forkhead-dependent pathway.

Authors:  Shino Nemoto; Maria M Fergusson; Toren Finkel
Journal:  Science       Date:  2004-12-17       Impact factor: 47.728

2.  Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.

Authors:  Yuan Yao; Angela M H Brodie; Nancy E Davidson; Thomas W Kensler; Qun Zhou
Journal:  Breast Cancer Res Treat       Date:  2010-07-10       Impact factor: 4.872

3.  An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha.

Authors:  Brian J Wilson; Annie M Tremblay; Geneviève Deblois; Guillaume Sylvain-Drolet; Vincent Giguère
Journal:  Mol Endocrinol       Date:  2010-05-19

4.  Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter.

Authors:  Armina A Kazi; Jenny M Jones; Robert D Koos
Journal:  Mol Endocrinol       Date:  2005-03-17

Review 5.  Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds.

Authors:  Jose Viña; Consuelo Borrás; Juan Gambini; Juan Sastre; Federico V Pallardó
Journal:  FEBS Lett       Date:  2005-04-14       Impact factor: 4.124

6.  hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.

Authors:  H Vaziri; S K Dessain; E Ng Eaton; S I Imai; R A Frye; T K Pandita; L Guarente; R A Weinberg
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

Review 7.  Steroid receptors in human breast cancer.

Authors:  Robert B Clarke; Elizabeth Anderson; Anthony Howell
Journal:  Trends Endocrinol Metab       Date:  2004-09       Impact factor: 12.015

8.  Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.

Authors:  Hwei-Ling Cheng; Raul Mostoslavsky; Shin'ichi Saito; John P Manis; Yansong Gu; Parin Patel; Roderick Bronson; Ettore Appella; Frederick W Alt; Katrin F Chua
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

9.  Evolution of the nuclear receptor gene superfamily.

Authors:  V Laudet; C Hänni; J Coll; F Catzeflis; D Stéhelin
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

10.  Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study.

Authors:  J A Cooper; T E Rohan; E L Cant; D J Horsfall; W D Tilley
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

View more
  66 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

Review 2.  Estrogens regulate life and death in mitochondria.

Authors:  Carolyn M Klinge
Journal:  J Bioenerg Biomembr       Date:  2017-08       Impact factor: 2.945

3.  MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1.

Authors:  Jian-Qiang Xu; Ping Liu; Ming-Jue Si; Xiao-Yi Ding
Journal:  Tumour Biol       Date:  2013-07-24

4.  Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.

Authors:  Kotha Subbaramaiah; Neil M Iyengar; Monica Morrow; Olivier Elemento; Xi Kathy Zhou; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

5.  Metal-binding effects of sirtuin inhibitor sirtinol.

Authors:  Eman A Akam; Ritika Gautam; Elisa Tomat
Journal:  Supramol Chem       Date:  2015-10-15       Impact factor: 1.688

6.  Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets.

Authors:  Maria Dalamaga
Journal:  World J Exp Med       Date:  2013-08-20

7.  Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway.

Authors:  C-L Song; H Tang; L-K Ran; B C B Ko; Z-Z Zhang; X Chen; J-H Ren; N-N Tao; W-Y Li; A-L Huang; J Chen
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis.

Authors:  Guiming Li; Paul Rivas; Roble Bedolla; Dinesh Thapa; Robert L Reddick; Rita Ghosh; Addanki P Kumar
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

9.  Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer.

Authors:  Hyojin Kim; Kyung-Hun Lee; In Ae Park; Yul Ri Chung; Seock-Ah Im; Dong-Young Noh; Wonshik Han; Hyeong-Gon Moon; Yoon Yang Jung; Han Suk Ryu
Journal:  Virchows Arch       Date:  2015-08-18       Impact factor: 4.064

10.  The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression.

Authors:  Sophie S B Giguère; Amanda J Guise; Pierre M Jean Beltran; Preeti M Joshi; Todd M Greco; Olivia L Quach; Jeffery Kong; Ileana M Cristea
Journal:  Mol Cell Proteomics       Date:  2015-12-09       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.